Neuland Laboratories Peer Comparison

Snapshot Summary

Neuland Laboratories Ltd. stands out in the Pharmaceuticals & Drugs sector with robust growth metrics, high profitability, and a strong balance sheet, positioning it as a leader among peers. It shows a remarkable revenue growth and EPS, along with low debt levels, making it an attractive investment compared to its peers, which exhibit mixed performance.

• Neuland Laboratories Ltd. leads in revenue growth and EPS metrics.
• Strong profitability indicated by high ROE and low debt levels.
• Several peers are overvalued with high PE ratios compared to earnings growth.

• Neuland Laboratories Ltd.: Highest revenue growth (YoY at 30.84%) and EPS growth (202.736), showcasing superior performance.
• Cipla Ltd.: Low PE ratio (23.73) with respectable growth and profitability, making it an attractive investment.
• Dr. Reddy's Laboratories Ltd.: Strong profitability metrics with a low PE ratio (15.50) and good revenue growth.

Stocks	CMP	Market Cap	P/E	ROCE (%)	Debt/Equity
NEULANDLAB	₹13,397.15	₹17,188.41Cr	66.26	33.51%	0.06
SUNPHARMA	₹1,563.35	₹3,75,099.26Cr	87.59	17.60%	0.04
DIVISLAB	₹6,091.05	₹1,61,698.50Cr	73.20	16.46%	-
CIPLA	₹1,587.60	₹1,28,217.27Cr	23.73	22.77%	0.01
TORNTPHARM	₹3,581.55	₹1,21,215.77Cr	61.53	24.28%	0.57
DRREDDY	₹1,280.30	₹1,06,835.27Cr	15.50	26.86%	0.07
MANKIND	₹2,518.95	₹1,03,926.59Cr	55.18	28.38%	0.02

Explore

Watchlists

Command Palette

Neuland Laboratories Peer Comparison

Snapshot Summary